title: Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies.
abstract: It is necessary to explore new treatments for recurrent head and neck malignancies (HNM) to avoid severe impairment of oro-facial structures and functions. Boron neutron capture therapy (BNCT) is tumor-cell targeted radiotherapy that has significant superiority over conventional radiotherapies in principle. We have treated with BNCT 42 times for 26 patients (19 squamous cell carcinomas (SCC), 4 salivary gland carcinomas and 3 sarcomas) with a recurrent and far advanced HNM since 2001. Results of (1) (10)B concentration of tumor/normal tissue ratios (T/N ratio) of FBPA-PET studies were SCC: 1.8-5.7, sarcoma: 2.5-4.0, parotid tumor: 2.5-3.7. (2) Therapeutic effects were CR: 12 cases, PR: 10 cases, PD: 3 cases NE (not evaluated): 1 case. Response rate was 85%. (3) Improvement of QOL such as a relief of severe pain, bleeding, and exudates at the local lesion, improvement of PS, disappearance of ulceration, covered with normal skin and preserved oral and maxillofacial functions and tissues. (4) Survival periods after BNCT were 1-72 months (mean: 13.6 months). Six-year survival rate was 24% by Kaplan-Meier analysis. (5) Adverse-events were transient mucositis and alopecia in most of the cases; three osteomyelitis and one brain necrosis were recognized. These results indicate that BNCT represents a new and promising treatment approach for advanced HNM.
authors.affiliation: Department of Oral and Maxillofacial Surgery, II Osaka University, Graduate School of Dentistry, Osaka, Japan. katoitsu@dent.osaka-u.ac.jp
authors.forename: Itsuro
authors.initials: I
authors.lastname: Kato
authors.forename: Yusei
authors.initials: Y
authors.lastname: Fujita
authors.forename: Akira
authors.initials: A
authors.lastname: Maruhashi
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Kumada
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Ohmae
authors.forename: Mitsunori
authors.initials: M
authors.lastname: Kirihata
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Imahori
authors.forename: Minoru
authors.initials: M
authors.lastname: Suzuki
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Sakrai
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Sumi
authors.forename: Soichi
authors.initials: S
authors.lastname: Iwai
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Nakazawa
authors.forename: Isao
authors.initials: I
authors.lastname: Murata
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Miyamaru
authors.forename: Koji
authors.initials: K
authors.lastname: Ono
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016754:Boron Neutron Capture Therapy / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000532:radiotherapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000532:radiotherapy*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging / Q000401:mortality / Q000532:radiotherapy*; D049268:Positron-Emission Tomography; D012468:Salivary Gland Neoplasms / Q000401:mortality / Q000532:radiotherapy; D012509:Sarcoma / Q000401:mortality / Q000532:radiotherapy